|
Why This Conference Stands Out
|
|
"We have tried to make this conference different - more interactive, creative and worthwhile."
- PCF Planning Committee
|
The leadership of the Pharmaceutical Compliance Forum (PCF), the sponsor of the Sixth Annual Pharmaceutical Regulatory and Compliance Congress, seeks to transform the event to reflect a new style of learning and knowledge exchange. To that end, a PCF special planning committee has been charged with the transformation of the Pharma Congress.
Under the leadership of the PCF special planning committee, the following initiatives have been put in place:
- The Pharma Congress will address the top five pharmaceutical compliance issues in 2006. Harvard Law Professor Arthur Miller will facilitate the discussion of these key compliance challenges. Discussion and problem solving around these key issues will be woven throughout the conference.
- The Pharma Congress will be interactive. In the plenary sessions each attendee will have a Meridia Audience response device with which he or she will be able to vote on questions put by the faculty. The attendee responses will be immediately projected on the session screens.
- The Pharma Congress will be built around a sophisticated hypothetical exercise that will continue throughout the conference. The hypothetical will include a variety of factual scenarios relating to issues raised by the top five pharmaceutical compliance issues in 2006. Attendees will be challenged to apply their new knowledge to specific hypothetical fact circumstances. Results of the hypothetical will be shared on the last day of the conference.
- Pharma Congress track sessions will be longer and will permit substantive learning and knowledge exchange, as well as the application of these bodies of knowledge to the changing Pharma Congress hypothetical.
- The Pharma Congress will feature two unique networking reception opportunities. The Monday evening opening networking reception will feature an opportunity to meet a number of key federal and state regulators and Capitol Hill staff specializing in pharmaceutical policy. The Tuesday networking reception will feature the exchange and presentation of company Codes of Conduct at poster boards throughout the Pharma Congress Exhibit Hall.
- The Pharma Congress will feature an extraordinary series of keynote speakers.
|
Who Should Attend
|
- Pharmaceutical and Health
- Care Executives and Board Members
- Compliance Executives
- Health Plan, Health System and Physician Organization
- Medical Directors
- Physicians
- Pharmacists
- Purchasers, including Private Employers and Public Purchasers
- Pharmaceutical Manufacturers
- Generic Pharmaceutical
- Manufacturers
- Site Management Organizations
- Clinical Research Organizations
- Pharmacy Benefit
|
- Management Companies
- Health Plans and Health Insurers
- Wholesale, Retail, Mail Order and Internet Pharmacies
- Health Care Attorneys and In-house Counsel
- Compliance Officers
- Privacy Officers
- Ethics Officers
- Food and Drug Law Attorneys
- Pharmaceutical Consultants
- Investment Bankers
- Venture Capitalists
- Health Care Regulators and Policy Makers
- Health Services Researchers and Academics
- Auditors
|
The Congress Goals and Objectives
|
- To identify and analyze the top five pharmaceutical compliance issues for 2006
- To utilize a hypothetical case study of a pharmaceutical manufacturer confronting a variety of regulatory and compliance challenges as a means of assessing risks and sharing best practice responses
- To freely exchange company codes of conduct as a means of sharing compliance best practices
- To provide a forum for leading regulators and qui tam counsel to express views and concerns in order to enhance communication among actors in the compliance field
|
About the Pharmaceutical Compliance Forum
|
|
The Pharmaceutical Compliance Forum (PCF) is a coalition of senior compliance officials and legal counsel from more than 50 of the largest pharmaceutical manufacturers. The PCF was founded in early-1999 by compliance professionals from the pharmaceutical industry to promote effective corporate compliance programs. The organization is open to others in the industry and has more than doubled in membership since its founding. The members meet twice a year, for one to two days, focusing on open and informal sharing of compliance information, best practices, and current developments in the field. For membership information, contact Arjun Rajaratnam, Esq., Vice President and Compliance Officer, Global Pharmaceuticals, GlaxoSmithKline at 919-483-9938 or Arjun.X.Rajaratnam@gsk.com.
|
PCF Special Planning Committee
|
- Arjun Rajaratnam, JD, Vice President and Compliance Officer, Global Pharmaceuticals, GlaxoSmithKline (Co chair)
- Brenton L. Saunders, JD, MBA, Senior Vice President, Global Compliance and Business Practices, Schering-Plough Corporation (Co chair)
- Bert Weinstein, Esq., Vice President, Corporate Compliance, Purdue Pharma LP (Co chair)
- John Alivernini, Esq., Vice President and Chief Compliance Officer, Wyeth Pharmaceuticals
- John T. Bentivoglio, Esq., Partner, King & Spalding LLP
- David B. Chandler, Ph.D., DABT, Manager, Compliance, 3M Pharmaceuticals
- Anthony L. Farino, Partner, US Leader, Life Sciences Advisory Practice, PricewaterhouseCoopers LLP
|
- Peter N. Grant, JD, Ph.D., President, Health Care Conference Administrators, LLC
- Keith M. Korenchuk, JD, MPH, Partner, McGuire Woods
- Steve Mohr, Esq., Deputy Compliance Officer, AstraZeneca
- Lori Queisser, Vice President and Chief Compliance Officer, Eli Lilly and Company
- Catherine A. Sazdanoff, Divisional Vice President, Ethics and Compliance, Abbott Laboratories
- Michael Shaw, Deputy Compliance Officer, Novartis Pharmaceuticals Corporation
- Paul J. Silver, Investigative and Dispute Services, Ernst & Young LLP
- Jonathan K. Sprole, Vice President and Deputy General Counsel and Chief Compliance Officer, Bristol-Myers Squibb Company
- Sheryl Vacca, CHC, West Coast Life Science and Health Care Regulatory Practice Leader, Deloitte & Touche LLP
|
|
|
